sosjtb
2 hours ago
Wow, comparing the Tuskegee Syphilis experiment to the Trump administration’s response to Covid is a stretch for even the most conspiracy driven whack job ideologue! Heck, it even belittles the racist policies of the US government at the time that allowed something like that happen, something that anyone with an ounce of decency let alone empathy would understand the horror that was inflicted on a population based on skin color.
Making any sort of false equivalence to the governments response to Covid and the vaccine with intentionally getting/letting people get infected with a disease is the projection that folks like Tucker and his pearl grasping sheeple lap up with joy! Creating a fake narrative is what makes them feel as if they are smarter than the person who can actually see through the bullshit. Reasonable people who can actually see through the bullshit is why even Fox News had to can his racist dog whistling ass, he is still there for them though, the tin foil hat wearing idiots still need someone to validate their nonsense and the internet allows them the platform for that to continue.
Science and reason is what ended the pandemic when it was killing on a daily basis. Fortunately there are more people of reason than there are conspiracy driven whack jobs, society can still continue to evolve and progress while they kick and scream nonsense that’s only validated through religious texts and mythology.
cowtown jay
21 hours ago
We know all we need to know about lenzilumab's safety and efficacy. We reported the LIVE-AIR trial results. Soon, the PREACH-M trial results will also be published, and based on the interim results, we know that will lead to Australian approval and other regulatory incentives, to include a PRV.
I recall that it was 300K doses we had to trash, because the product reached the expiration date. I also know that other manufacturers got extensions of the arbitrary expiration dates.
Management will succeed in getting lenz approved. Management will accomplish this overseas, and that will lead to US authorization, especially if HIVICRON proves to be more lethal than anything we have yet seen. I only hope that lenz will be able to help to restore the innate immune response system, which has been severely damaged by the mRNA vaccines.
cowtown jay
21 hours ago
How the hell do you demonstrate the graft and corruption of regulatory agencies, when THEY control the authorization of your drug, and when THEY are major investors in the mRNA vaccine manufacturers whose revenues will be smashed by lenz and the lenz-enhanced Novavax vaccine, and when THEIR scientists are receiving royalties, and when THEY are receiving the majority of their funding from their Big Pharma partners/sponsors?
Humanigen changed their primary endpoint to better align with the government's trial design.
Of course ACTIV-5 didn't meet the endpoint. The trial was designed to fail. We knew ACTIV-5 would fail, when CRP levels of the critically ill patients get >150mg/L of CRP.
Necessity, as I have always said, will lead to our authorization and approval. NOBODY believes in the mRNA vaccines, now that the truth about Serious Adverse Events are being reported. Pfizer trial patients had 36% more SAE's than the placebo group. And with a highly virulent strain of omicron (HIVICRON) expected, lenz will be the only safe and effective treatment on the market.
cowtown jay
22 hours ago
In October of 2020, Tucker interviewed Durrant about lenzilumab being a "Potential breakthrough coronavirus treatment." This was only about 7 months after covid hit our shores. This discovery of lenzilumab's potential to treat covid was the result of a Case Cohort Study led by Mayo Clinic, and included Humanigen's Dr. Cameron Durrant, Dr. Dale Chappell, and others, as trial investigators. A matter of 'all hands on deck.'
Results of the Case Cohort Study were published in June of 2020, and showed:
"Twelve patients were treated with lenzilumab. Clinical improvement was observed in 11 out of 12 (92%), with a median time to discharge of 5 days. There was a significant improvement in oxygenation: The proportion of patients with SpO2/FiO2 < 315 at the end of observation was 8% vs. compared to 67% at baseline (p=0.00015). A significant improvement in mean CRP and IL-6 values on day 3 following lenzilumab administration was also observed (137.3 mg/L vs 51.2 mg/L, p = 0.040; 26.8 pg/mL vs 16.1 pg/mL, p = 0.035; respectively). Cytokine analysis showed a reduction in inflammatory myeloid cells two days after lenzilumab treatment. There were no treatment-emergent adverse events attributable to lenzilumab, and no mortality in this cohort of patients with severe COVID-19 pneumonia."
https://pubmed.ncbi.nlm.nih.gov/32587983/
Here's the interview.
https://www.foxnews.com/video/6197198838001
Contemporaneous to Tucker's interview, Big Pharma began reporting the efficacy of their vaccines, in which most were claiming efficacy just slightly better than lenzilumab. Of course, THOSE claims were proven false. And vaccines were redefined from "preventing infection," to reducing hospitalizations and deaths.
Tucker's second interview of Durrant, in October of 2021 (a full year after Tucker's interview to discuss how lenzilumab's efficacy was demonstrated), was intended to expose how "Treatments for Covid Are Being Ignored By FDA."
https://www.realclearpolitics.com/video/2021/10/01/humanigen_ceo_durrant_treatments_for_covid_are_being_ignored_by_fda.html
By this time, Humanigen had reported, in March of 2021, the positive topline results of their LIVE-AIR trial.
https://www.businesswire.com/news/home/20210329005301/en/
You've been here since 2015, just as I have. It's despicable that you would now claim that these results have been a scam. I have made it clear as day that the NIAID/NIH ACTIV-5 government-sponsored trial was designed to fail, by including late-stage patients in Ordinal Scales 5, 6, and 7, and excluding patients in Ordinal Scale 4, who accounted for 78% of the LIVE-AIR trial population. Humanigen included early-stage patients only in Ordinal Scales 4 and 5.
ACTIV-5 patient inclusion criteria:
Illness of any duration, and requiring, just prior to randomization, supplemental oxygen (any flow), mechanical ventilation or Extracorporeal Membrane Oxygenation (ECMO) (ordinal score 5, 6, or 7).
https://clinicaltrials.gov/study/NCT04583969?intr=lenzilumab&rank=2
LIVE-AIR patient inclusion criteria
SpO2 ≤ 94% on room air and/or require low-flow supplemental oxygen and/or require high-flow oxygen support or NIPPV
https://clinicaltrials.gov/study/NCT04351152?intr=lenzilumab&rank=3
cowtown jay
1 day ago
He didn't take any heed of your advice, eb, and instead, his first two posts following yours, were the two worst posts that he has written.
But I know of a guy that blew-off a chance to meet with Durrant, so what can you say? I know of another guy that should know better, but thinks our trial results were not statistically significant. We all have made regrettable decisions.
cowtown jay
2 days ago
Excess deaths just go on and on and on. The most recent data for the US reflects a total of 366,894 excess deaths from the start of 2023, through week 16 of 2024. Those excess deaths are 10% higher than what would normally be expected. And this is before the projected highly virulent form of omicron (HIVICRON) begins to circulate, which I think will be more deadly than anything we have yet seen. I also think only the lenz-enhanced Novavax vaccine (if it is developed with Sanofi), will be able to prevent infections, as true vaccines are supposed to do, and that only the therapeutic version of lenz will be able to save the lives of infected patients. That's partly why I post here as often as I do. I don't want to see what happened to my wife, happen on a population scale. Also, I would like to have lenz available to treat whatever is causing my inflammation, and of course, as a small shareholder, I want to see lenz get regulatory approval and reach it's market value potential.
Here's the source data in the video. I also left a comment on Dr. Campbell's site, following the video.
@JayBooth-oj2dy
32 minutes ago
"Humanigen (Taran Therapeutics) Announces Peer-Reviewed Publication in Thorax Supporting Early Treatment of Hospitalized COVID-19 Patients with Lenzilumab Guided by C-Reactive Protein
Jul 06, 2022
Lenzilumab improved clinical outcomes in hospitalized non-mechanically ventilated hypoxic COVID-19 patients.2 The greatest benefit was observed in those with a CRP level below 150 mg/L in the LIVE-AIR study. In this sub-analysis, lenzilumab improved the likelihood of (Survival Without Ventilation) SWOV compared with placebo (HR: 2.54; p=0.0009), demonstrated reduced odds (OR 0.38; p=0.0053) and a 62% reduction in the relative risk of progressing to mechanical ventilation or death in lenzilumab-treated patients, there were more ventilator-free days (p=0.0045), fewer ICU days (p=0.0458), and improved time-to-recovery (p=0.0219).1
https://ir.humanigen.com/English/news/news-details/2022/Humanigen-Announces-Peer-Reviewed-Publication-in-Thorax-Supporting-Early-Treatment-of-Hospitalized-COVID-19-Patients-with-Lenzilumab-Guided-by-C-Reactive-Protein/default.aspx
Lenzilumab (lenz) is variant-agnostic. It binds GM-CSF, modulating the immune response, and prevents cytokine storm. I fervently hope that lenz gets regulatory approval, and saves as many lives as possible before and after the arrival of Geert's HIVICRON.
cowtown jay
2 days ago
"As (far) as more common blood cancer like Leukemia, there is currently no cure for it..."
Last year, Humanigen, "...extended previously
reported results by presenting additional, statistically significant hematologic improvements and reductions in
inflammatory markers from lenzilumab, its investigational drug, in a Phase 2/3 trial of treatment-naïve participants
with chronic myelomonocytic leukemia and RAS-pathway mutations.
The additional data demonstrate that in all 10 participants with at least three months of treatment with both
lenzilumab and azacitidine, blood monocyte count decreased fivefold (P=0.03), the percentage of blast cells and
pro-monocytes decreased more than twofold (P=0.04), and C-reactive protein decreased more than threefold
(P=NS) with improvements noted after both 3 months and 6 months of this combination treatment. These results
suggest lenzilumab may normalize hematologic and inflammatory aberrations in CMML and improve the condition
of participants. All ten evaluable participants had a rapid clinical response...
The incidence of CMML in the US, UK, and Australia is about 1,700 patients annually.9 As an orphan disease,
lenzilumab may qualify for certain regulatory and commercial advantages that could expedite development and
potential approval. Humanigen and the Principal Investigator are assessing regulatory pathways that may enable
early results to support a regulatory submission and potential approval by the Therapeutic Goods Administration in
Australia."
https://s28.q4cdn.com/539885110/files/doc_news/Humanigen-Presents-Promising-New-Hematologic-Data-from-PREACH-M-Trial-for-Chronic-Myelomonocytic-Leukemia-Treatment-at-the-2023-Europ-OYZCQ.pdf
Regulatory incentives include a potential Priority Review Voucher, with a value of ~$125M+.
If you understand what was said about lenzilumab's Method of Action, then maybe you'll see how wrong you were about this in your post.
cowtown jay
2 days ago
You know, ZEN, they're going to restrict you to "emoji only" if this laughable argument is the best you can do. I've had one sip of coffee, which isn't enough to give your post the shredding it deserves. Even the purists here should be able to counter your claims, if they put their minds to it.
It's not that the day is young, it's off to a false start, which is often the case for me. But I'll be back later, after I get more sleep. But thanks for your post. It will motivate me to marshal a fitting response, if no one else does before I get back to this.
US-JUSTICE
3 days ago
the lenzi molecule or patent that hgenq owns is what cowtown jay is raving about and was in stage 3 clinical studies but didn't show enough efficacy to cure a very rare blood disorder or blood cancer and is only 3 in 10,000 people type of blood disorder. 341 000 000 americans x .0003= 100,000 patients at $10,000/cure is $1,000,000,000 that is where the estimate or potential market for this Lenzi MOLECULE. As for as more common blood cancer like Leukemia, there is currently no cure for it and experimental drug as far as I know. these blood cancer disease are not easy to cure without side effects. The blood contains many cells and introducing a new chemical can have unknown side effects.
As for corvid use, it's mainly anti-viral effects boosting the bodies own immune system in creating more white blood cells quickly or artificially very fast before a virus can over run the bodies immune system to heal itself. that market if it works in the 10 billion market as more people choose not to take vaccines or boosters. mRNA vaccines like astra zeneca admit to side effects and vaccines are already waning. As a result, post treatment of viral infection is only option as people don't want to take vaccines as the vaccine side effect is worse than the virus infection. Corvid infection are rising as new variants or vaccine wanes over time. There are probably lots of drugs like lenzi to treat POST infection for people are not vaccinated or no longer interested in booster shots or taking their 5 or 6 shot of mRNA shots.
cowtown jay
3 days ago
I don't agree that the value of the IP was/is based upon a, "...potential for 1 billion in sales." That came from management's initial revenue estimate, which was capacity-constrained to 100K treatments, at a cost of $10K per treatment.
Is that a lost opportunity for Humanigen or Taran (HOT)? No. That opportunity was delayed, but it also created a much larger market demand. I thought that it might, as a result of our countermeasures only making matters worse.
In that regard, we have the potentially imminent arrival of HIVICRON (Highly Virulent Omicron variant). Dr. Rob Rennebohm, MD, summarized Dr. Geert Vanden Bossche’s work in this field, as seen below.
https://notesfromthesocialclinic.org/wp-content/uploads/2024/06/COVID-ANALYSIS-260-GEERTS-ANALYSIS-FINAL-13-on-6-19-24.pdf
For those that might prefer a video presentation of the information, you can see it here.
In my opinion:
HOT, working with Novavax and Sanofi, will be able to get as much of the lenz-enhanced Novavax covid vaccine into the market, as will be required. As I expect that we are likely to form a merger entity with Sanofi and/or Novavax, I will look forward to that entity launching a reformulated therapeutic version of lenz to treat non-hospitalized covid patients while their CRP levels are still low. Lenz demonstrated 8-fold improved treatment outcomes when administered early, when CRP levels were